Cochlear Ltd (ASX: COH) shares went into freefall in late April after a brutal earnings downgrade shocked the market.
The stock plunged from around $168 to near $90 in a matter of days — a staggering 46% wipeout. It's not every day a blue chip healthcare name gets smashed like this. While it managed to claw back slightly to finish April around $94, the damage has been done.
So, what just happened at the end of April and could a recovery be on the cards?
Image source: Getty Images
Sharp cut, delayed surgeries
The $6 billion ASX company leads the global cochlear implant market with about 50% global market share. Cochlear shares are now down roughly 65% year to date in 2026, with the bulk of that decline triggered by a weak trading update released on 22 April.
There's no dressing it up. The update disappointed. The company slashed its FY26 underlying net profit guidance to between $290 million and $330 million. That's a sharp cut from its previous $435 million to $460 million range and a significant downgrade for a business known for consistency.
What's driving the weakness? Demand has softened in key developed markets, with fewer hearing implant procedures taking place. Cochlear also flagged disruptions in the Middle East, where ongoing conflict has led to cancelled orders and delayed deliveries.
At the same time, some patients appear to be delaying surgeries, treating them as discretionary in the short term. Referrals have slowed, and procedures are being pushed out. Importantly, that doesn't mean demand has disappeared.
Growing pool of patients
Cochlear remains the global leader in implantable hearing solutions, backed by decades of research and development. Around 13% of its revenue continues to be reinvested into innovation, a sign the long-term strategy remains intact.
There is also a large and growing pool of patients with hearing loss, particularly among ageing populations. Management of Cochlear shares continues to point to a "significant, unmet and addressable clinical need" underpinning future growth.
In other words, this looks more like a timing issue than a structural collapse.
Uncertainty is high
Still, the market isn't reacting without reason. Earnings have taken a clear hit, and near-term visibility is now clouded.
But here's where things get interesting. At around $94, Cochlear shares are trading on a little over 19 times FY26 earnings, a level rarely seen for a company of this quality. That's starting to divide opinion.
Some brokers remain optimistic. Jarden has a price target on Cochlear shares of $169, suggesting almost 80% upside if conditions normalise. Other analysts are more cautious. Macquarie has slashed its target from $239 to $115, while Morgans sits in the middle with a hold rating and a $107.17 target.
The spread tells the story: uncertainty is high.
Foolish Takeaway
Cochlear shares' collapse late April was dramatic and justified by a sharp downgrade in earnings expectations. But the long-term story hasn't disappeared. If delayed demand returns and execution stabilises, a recovery could follow.
For now, though, this ASX healthcare giant sits at a crossroads, caught between short-term pain and long-term potential.
